<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04443478</url>
  </required_header>
  <id_info>
    <org_study_id>CLASS-10</org_study_id>
    <nct_id>NCT04443478</nct_id>
  </id_info>
  <brief_title>Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction Cancer</brief_title>
  <official_title>Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Siewert Type II/III Adenocarcinoma of Esophagogastric Junction: an Exploratory, Prospective, Observational, IDEAL Stage 2, Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changzhi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing hospital of air force Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Qinghai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mediastinal lymph node dissection has been adopted as standard treatment for adenocarcinoma
      of esophagogastric junction(AEJ). This multi-center, exploratory, prospective, cohort study
      aims at provide standard technical details of laparoscopic mediastinal lymph node dissection,
      and explore the potential clinical effects, gather key information for following study
      regarding sample size calculation, primary outcome and feasibility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Lower mediastinal lymph node dissection has been adopted as standard by
      treatment guideline for adenocarcinoma of esophagogastric junction(AEJ), but the effect of
      laparoscopic mediastinal lymph node dissection remains unknown. The aim of this study is to
      provide standard technical details of laparoscopic mediastinal lymph node dissection, and
      explore the potential clinical effects, gather key information for following study regarding
      sample size calculation, primary outcome and feasibility. This study report intervention
      development, governance procedures and selection and reporting of outcomes to optimize
      methods for using the Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL)
      framework for surgical innovation that informs evidence-based practice.

      Methods and analysis: This is an IDEAL stage II, prospective, parallel control, open label,
      multi-center and exploratory study. The inclusion criteria is Siewert II/ III, AEJ,
      cT2-4aN0-3M0(AJCC-8th Gastric Cancer TNM stage manual), decide to receive radical
      gastrectomy, without preoperative anti-neoplastic therapy. Lymphadenectomy should include at
      least No.110, No.111 and part of No. 112(112pul and 112aoA). Allocation is not assigned by
      investigator. The primary outcome is the number of lymph node dissected in No.110, No.111,
      secondary outcome include complication, surgery length, postoperative death, R0 resection
      rate, etc. Expected sample size is 518 in each group, thus has 80% power to detect a
      difference of 0.17 in the average number of lower mediastinal lymph node dissected in between
      two groups.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>number of lymph node dissected in No.110&amp;111</measure>
    <time_frame>immediately after the pathology report issued</time_frame>
    <description>number of lymph node dissected in No.110&amp;111</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complication during Lower Mediastinal Lymphadenectomy</measure>
    <time_frame>immediately after the surgery</time_frame>
    <description>Complication during Lower Mediastinal Lymphadenectomy &amp; anastomosis, including damage of pericardium, esophagus, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative complication after Lower Mediastinal Lymphadenectomy</measure>
    <time_frame>Day 30 after surgery</time_frame>
    <description>Postoperative complication after Lower Mediastinal Lymphadenectomy, including leakage, bleeding, etc, complication related with Lower Mediastinal Lymphadenectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time length of Lower Mediastinal Lymphadenectomy</measure>
    <time_frame>immediately after the surgery</time_frame>
    <description>Time length of Lower Mediastinal Lymphadenectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Postoperative complication</measure>
    <time_frame>Day 30 after surgery</time_frame>
    <description>Any complication within 30d after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative death</measure>
    <time_frame>Day 30 after surgery</time_frame>
    <description>death within 30 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of unscheduled reoperation</measure>
    <time_frame>Day 30 after surgery</time_frame>
    <description>reoperation within 30 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of unscheduled readmission</measure>
    <time_frame>Day 30 after surgery</time_frame>
    <description>unscheduled readmission within 30 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>immediately after the pathology report issued</time_frame>
    <description>R0 resection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal margin length</measure>
    <time_frame>30minutes after removal of tumor</time_frame>
    <description>from proximal tumor margin to proximal margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence of lower mediastinal area in 3 years</measure>
    <time_frame>Year 3 after surgery</time_frame>
    <description>Local recurrence of lower mediastinal area in 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cancer specific death in 3 years</measure>
    <time_frame>Year 3 after surgery</time_frame>
    <description>Rate of cancer specific death in 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival in 3 years</measure>
    <time_frame>Year 3 after surgery</time_frame>
    <description>Recurrence free survival in 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in 3 years</measure>
    <time_frame>Year 3 after surgery</time_frame>
    <description>Overall survival in 3 years</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality evaluation index of Lower Mediastinal Lymphadenectomy</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>surgical characteristics that are directly related to the safety outcome of surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Learning curve of Lower Mediastinal Lymphadenectomy</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>refers to the number of surgical cases corresponding to the transition point</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment tendency of surgeons and patients</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>the proportion of persons willing to receive treatment in randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients that can be screened and successfully recruited</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>The number of patients that can be screened, excluded, successfully recruited, intervented, and followed up throughout each phase of the study.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1036</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Laparoscopic Surgery</arm_group_label>
    <description>Lower Mediastinal Lymphadenectomy should be finished via laparoscopic method.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Surgery</arm_group_label>
    <description>Lower Mediastinal Lymphadenectomy should be finished via open method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical gastrectomy with dissection of lower mediastinal lymph node</intervention_name>
    <description>Radical gastrectomy for gastric cancer should be consistent with Japanese gastric cancer treatment guideline. In particular, lymphadenectomy should include at least No.110, No.111 and part of No. 112(112pul and 112aoA)</description>
    <arm_group_label>Laparoscopic Surgery</arm_group_label>
    <arm_group_label>Open Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pathologically Confirmed esophageal gastric adenocarcinoma, clinical stage cT2-4aN3M0(AJCC
        - 8th gastric cancer tumor TNM staging), Siewert Ⅱ/Ⅲ, receive surgical treatment without
        preoperative treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old;

          -  Karnofsky score ≥70%;Or ECOG score ≤2;

          -  Preoperative pathological biopsy confirmed adenocarcinoma.

          -  According to gastroscopy, abdominal CT or upper gastrointestinal angiography, the
             tumor site conforms to the definition of esophageal and gastric junction
             adenocarcinoma in the &quot;Chinese expert consensus&quot;, that is, the tumor center is within
             5cm above and below the esophagogastric anatomical junction and crosses or touches the
             esophagogastric junction;

          -  Length of esophageal invasion ≤2cm;

          -  By abdominal contrast-enhanced CT/MRI, the clinical stage was CT2-4aN0-3M0 (according
             to AJCC-8th TNM tumor stage);

          -  Subject's blood routine and biochemical indicators meet the following standards:
             hemoglobin ≥80g/L; Absolute count of neutrophils (ANC) ≥1.5×109/L; Platelet
             ≥75×109/L;ALT and AST≤2.5 times the normal upper limit; ALP≤2.5 times the normal upper
             limit; Serum total bilirubin ≤1.5 times the normal upper limit; Serum creatinine ≤ the
             normal upper limit; Serum albumin ≥30g/L;

          -  Obtain written informed consent.

        Exclusion Criteria:

          -  Received any chemotherapy, radiotherapy, targeted therapy or immunotherapy for
             esophageal and gastric junction adenocarcinoma;

          -  Lymph node Bulky N2 status was diagnosed by abdominal CT/MRI, that is, at least 1
             lymph node diameter ≥3cm or 3 consecutive lymph nodes, each diameter ≥ 1.5cm;

          -  Multiple malignant lesions in the stomach;

          -  Pregnant or breast-feeding women;

          -  A history of uncontrolled epilepsy, central nervous system disease or mental disorder;

          -  Prior upper abdominal surgery (except laparoscopic cholecystectomy);

          -  Patients with other malignant diseases in the last 5 years, except cured skin cancer
             and carcinoma in situ of the cervix;

          -  Clinically severe (i.e., active) heart disease, such as symptomatic coronary heart
             disease, New York Heart Association (NYHA) class II or more congestive heart failure
             or severe arrhythmia requiring drug intervention, or a history of myocardial
             infarction within the last 6 months;

          -  A history of cerebral infarction or cerebral hemorrhage in the last 6 months;

          -  Those who need immunosuppressive therapy for organ transplantation;

          -  Severe uncontrolled recurrent infections or other serious uncontrolled concomitant
             diseases;

          -  moderate or severe renal impairment, or serum creatinine &gt; normal upper limit (ULN);

          -  Emergency surgery is required due to tumor emergencies (bleeding, perforation and
             obstruction);

          -  FEV1 &lt; 50% of estimated value;

          -  those who have received study drugs or preparations/treatments (participants in other
             trials) within 4 weeks prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fei Shan, MD</last_name>
      <email>shanfei@hsc.pku.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhemin Li, MD</last_name>
      <email>tagzhemin@outlook.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc. 1994 Apr;4(2):146-8. Erratum in: Surg Laparosc Endosc. 2013 Oct;23(5):480.</citation>
    <PMID>8180768</PMID>
  </reference>
  <reference>
    <citation>Markar SR, Dabakuyo-Yonli TS, Piessen G. Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. Reply. N Engl J Med. 2019 Apr 25;380(17):e28. doi: 10.1056/NEJMc1901650.</citation>
    <PMID>31018084</PMID>
  </reference>
  <reference>
    <citation>Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg. 2016 Jan;263(1):28-35. doi: 10.1097/SLA.0000000000001346.</citation>
    <PMID>26352529</PMID>
  </reference>
  <reference>
    <citation>Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Chen P, Liu H, Zheng C, Liu F, Yu J, Li Z, Zhao G, Chen X, Wang K, Li P, Xing J, Li G. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. J Clin Oncol. 2016 Apr 20;34(12):1350-7. doi: 10.1200/JCO.2015.63.7215. Epub 2016 Feb 22.</citation>
    <PMID>26903580</PMID>
  </reference>
  <reference>
    <citation>Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Hu Y, Liu H, Zheng C, Li P, Xie J, Liu F, Li Z, Zhao G, Yang K, Liu C, Li H, Chen P, Ji J, Li G; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. JAMA. 2019 May 28;321(20):1983-1992. doi: 10.1001/jama.2019.5359.</citation>
    <PMID>31135850</PMID>
  </reference>
  <reference>
    <citation>Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2020 Feb 14. doi: 10.1007/s10120-020-01042-y. [Epub ahead of print]</citation>
    <PMID>32060757</PMID>
  </reference>
  <reference>
    <citation>Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, Yoshida K, Daiko H, Sakuramoto S, Yoshikawa T, Kunisaki C, Seto Y, Tamura S, Shimokawa T, Sano T, Kitagawa Y. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Ann Surg. 2019 Aug 8. doi: 10.1097/SLA.0000000000003499. [Epub ahead of print]</citation>
    <PMID>31404008</PMID>
  </reference>
  <reference>
    <citation>Sugita S, Kinoshita T, Kaito A, Watanabe M, Sunagawa H. Short-term outcomes after laparoscopic versus open transhiatal resection of Siewert type II adenocarcinoma of the esophagogastric junction. Surg Endosc. 2018 Jan;32(1):383-390. doi: 10.1007/s00464-017-5687-6. Epub 2017 Jun 27.</citation>
    <PMID>28656339</PMID>
  </reference>
  <reference>
    <citation>Sugita S, Kinoshita T, Kuwata T, Tokunaga M, Kaito A, Watanabe M, Tonouchi A, Sato R, Nagino M. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type II adenocarcinoma of the esophagogastric junction. Surg Endosc. 2020 Feb 5. doi: 10.1007/s00464-020-07406-w. [Epub ahead of print]</citation>
    <PMID>32025923</PMID>
  </reference>
  <reference>
    <citation>Huang CM, Lv CB, Lin JX, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lu J, Cao LL, Lin M, Tu RH. Laparoscopic-assisted versus open total gastrectomy for Siewert type II and III esophagogastric junction carcinoma: a propensity score-matched case-control study. Surg Endosc. 2017 Sep;31(9):3495-3503. doi: 10.1007/s00464-016-5375-y. Epub 2016 Dec 15.</citation>
    <PMID>27981384</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jiafu Ji</investigator_full_name>
    <investigator_title>President of Beijing Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>esophagogastric junction</keyword>
  <keyword>lower mediastinal lymphadenectomy</keyword>
  <keyword>laparoscopic gastrectomy</keyword>
  <keyword>IDEAL framework</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be shared after the publication of the results.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After the publication.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

